Mirae Asset Global Investments Co. Ltd. Increases Position in Inhibrx, Inc. (NASDAQ:INBX)

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Inhibrx, Inc. (NASDAQ:INBX) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,494 shares of the company’s stock after buying an additional 1,331 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Inhibrx were worth $779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INBX. Hennion & Walsh Asset Management Inc. grew its stake in Inhibrx by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 27,731 shares of the company’s stock worth $509,000 after buying an additional 13,098 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in Inhibrx during the 3rd quarter worth $232,000. Swiss National Bank grew its stake in Inhibrx by 2.1% during the 3rd quarter. Swiss National Bank now owns 57,600 shares of the company’s stock worth $1,057,000 after buying an additional 1,200 shares during the last quarter. Citigroup Inc. grew its stake in Inhibrx by 3.4% during the 3rd quarter. Citigroup Inc. now owns 49,244 shares of the company’s stock worth $904,000 after buying an additional 1,611 shares during the last quarter. Finally, Eventide Asset Management LLC purchased a new position in Inhibrx during the 3rd quarter worth $7,964,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Inhibrx Stock Up 0.7 %

Inhibrx stock opened at $34.38 on Thursday. The company has a debt-to-equity ratio of 4.78, a quick ratio of 5.25 and a current ratio of 5.24. The business’s 50-day simple moving average is $35.66 and its two-hundred day simple moving average is $30.11. The company has a market cap of $1.63 billion, a PE ratio of -6.83 and a beta of 2.91. Inhibrx, Inc. has a fifty-two week low of $14.31 and a fifty-two week high of $39.79.

Inhibrx (NASDAQ:INBX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.66). The firm had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. Equities analysts anticipate that Inhibrx, Inc. will post -4.34 EPS for the current year.

Wall Street Analysts Forecast Growth

INBX has been the topic of several research analyst reports. JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Tuesday, January 23rd. Lifesci Capital downgraded Inhibrx from an “outperform” rating to a “market perform” rating in a research note on Tuesday, January 23rd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.